淋巴瘤相关的噬血细胞性综合征(LAHS)是一类恶性疾病，病情恶化迅速，死亡率较高。本研究旨在发现血清sCD25/ferritin比值以及细胞因子在协助LAHS诊断中的意义。我们回顾性分析了82例HLH作为首发表现的LAHS患者的临床数据，并根据淋巴瘤病理诊断将其分为B-LAHS组和T/NK-LAHS组进行比较。根据评估DEP/L-DEP诱导治疗2周后的疗效，将LAHS患者分为反应组和非反应组，比较可能有价值的指标。血清sCD25/ferritin比值和MCP-1水平在B-LAHS组和T/NK-LAHS组之间显著不同(P = 0.001，P = 0.022)。sCD25/ferritin比值> 7.8倾向于提示B-LAHS的诊断(AUC = 0.71，95％ CI：0.596-0.823)，当与MCP-1联合使用时，sCD25/ferritin比值的预测价值更好(AUC = 0.81，95％ CI：0.699-0.922)。sCD25/ferritin比值在对诱导治疗有或无反应的两组之间也显著不同(P = 0.002)，得出一个最佳的截止值为11.48。sCD25/ferritin比值> 11.48倾向于提示患者的LAHS对诱导治疗有反应。本研究揭示了血清sCD25/ferritin比值与MCP-1结合是识别以HLH为首发表现的LAHS并预测淋巴瘤是否为B细胞或T/NK细胞起源的有效预测因子。sCD25/ferritin比值也可用于预测LAHS对诱导治疗的早期反应。 ©2023.作者，Springer-Verlag GmbH Germany的独家许可人，Springer Nature的一部分。

Lymphoma-associated haemophagocytic syndrome (LAHS) is a group of malignant diseases with rapid progression and a high mortality rate. Our study aimed to discover the significance of serum sCD25/ferritin ratio as well as cytokines in assisting the diagnosis of LAHS.We retrospectively analyzed the clinical data of 82 patients with LAHS with hemophagocytic lymphohistiocytosis (HLH) as the first manifestation and divided them into B-LAHS group and T/NK-LAHS group according to lymphoma pathological diagnosis for comparison. And patients with LAHS were divided into responding group, non-responding group according to the assessment of efficacy after receiving DEP/L-DEP induction therapy for 2 weeks to compare possible valuable indicators.Serum sCD25/ferritin ratio and MCP-1 levels were significantly different between B-LAHS and T/NK-LAHS groups (P = 0.001, P = 0.022). An sCD25/ferritin ratio > 7.8 tended to suggest a diagnosis of B-LAHS (AUC = 0.71, 95% CI: 0.596-0.823), and the sCD25/ferritin ratio had better predictive value when combined with MCP-1 (AUC = 0.81, 95% CI: 0.699-0.922). The sCD25/ferritin ratio was also significantly different between the two groups responding or not responding to induction therapy (P = 0.002), yielding an optimal cutoff value of 11.48. An sCD25/ferritin ratio > 11.48 tended to suggest that the patient's LAHS was responsive to induction therapy.Our study reveals that serum sCD25/ferritin ratio combined with MCP-1 is a valid predictor for identifying LAHS with HLH as the first manifestation and may assist in predicting whether the lymphoma is of B-cell or T/NK-cell origin. The sCD25/ferritin ratio can also be used to predict the early response of LAHS after induction therapy.© 2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.